B. Riley analyst Yuan Zhi last night initiated coverage of Tango Therapeutics with a Buy rating and $16 price target. Tango is a clinical-stage biotech company developing targeted therapies by identifying novel synthetic lethal targets, the analyst tells investors in a research note. The firm anticipates additional upside potential post TNG908’s data readout in mid 2024, which may it says also validate the company’s proprietary drug discovery platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TNGX:
- Tango Therapeutics to present data on PRMT5 inhibitors at SNO meeting
- Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting
- Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights
- Tango Therapeutics reports Q3 EPS (23c), consensus (34c)
- new option listings and one option delisting on November 1st
